Thermo Fisher Scientific Inc - Asset Resilience Ratio
Thermo Fisher Scientific Inc (TMO) has an Asset Resilience Ratio of 1.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Thermo Fisher Scientific Inc (TMO) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1995–2024)
This chart shows how Thermo Fisher Scientific Inc's Asset Resilience Ratio has changed over time. See what is Thermo Fisher Scientific Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Thermo Fisher Scientific Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Thermo Fisher Scientific Inc (TMO) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.56 Billion | 1.52% |
| Total Liquid Assets | $1.56 Billion | 1.52% |
Asset Resilience Insights
- Limited Liquidity: Thermo Fisher Scientific Inc maintains only 1.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Thermo Fisher Scientific Inc Industry Peers by Asset Resilience Ratio
Compare Thermo Fisher Scientific Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Thermo Fisher Scientific Inc (1995–2024)
The table below shows the annual Asset Resilience Ratio data for Thermo Fisher Scientific Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.72% | $5.57 Billion | $97.32 Billion | -0.47pp |
| 2023-12-31 | 6.19% | $6.11 Billion | $98.73 Billion | -2.59pp |
| 2022-12-31 | 8.78% | $8.53 Billion | $97.15 Billion | +4.07pp |
| 2021-12-31 | 4.71% | $4.48 Billion | $95.12 Billion | -10.29pp |
| 2020-12-31 | 14.99% | $10.35 Billion | $69.05 Billion | +10.82pp |
| 2019-12-31 | 4.17% | $2.44 Billion | $58.38 Billion | +0.43pp |
| 2018-12-31 | 3.75% | $2.11 Billion | $56.23 Billion | +1.37pp |
| 2017-12-31 | 2.37% | $1.34 Billion | $56.67 Billion | +0.63pp |
| 2016-12-31 | 1.75% | $802.00 Million | $45.91 Billion | +1.71pp |
| 2015-12-31 | 0.03% | $13.60 Million | $40.83 Billion | -0.03pp |
| 2014-12-31 | 0.07% | $28.70 Million | $42.85 Billion | +0.04pp |
| 2013-12-31 | 0.03% | $8.30 Million | $31.86 Billion | +0.01pp |
| 2012-12-31 | 0.02% | $4.30 Million | $27.44 Billion | 0.00pp |
| 2011-12-31 | 0.02% | $4.30 Million | $26.83 Billion | -0.03pp |
| 2010-12-31 | 0.04% | $8.90 Million | $21.39 Billion | +0.01pp |
| 2009-12-31 | 0.03% | $7.10 Million | $21.60 Billion | 0.00pp |
| 2008-12-31 | 0.04% | $7.50 Million | $21.09 Billion | -0.03pp |
| 2007-12-31 | 0.07% | $14.10 Million | $21.21 Billion | -0.16pp |
| 2006-12-31 | 0.23% | $48.16 Million | $21.26 Billion | -1.67pp |
| 2005-12-31 | 1.90% | $80.66 Million | $4.25 Billion | -3.29pp |
| 2004-12-31 | 5.18% | $185.37 Million | $3.58 Billion | +1.81pp |
| 2003-12-31 | 3.37% | $114.33 Million | $3.39 Billion | -11.34pp |
| 2002-12-31 | 14.71% | $536.43 Million | $3.65 Billion | -4.74pp |
| 2001-12-31 | 19.45% | $744.00 Million | $3.83 Billion | +8.74pp |
| 2000-12-31 | 10.71% | $521.00 Million | $4.86 Billion | -0.02pp |
| 1999-12-31 | 10.73% | $556.00 Million | $5.18 Billion | -7.45pp |
| 1998-12-31 | 18.18% | $1.15 Billion | $6.33 Billion | +2.15pp |
| 1997-12-31 | 16.03% | $929.00 Million | $5.80 Billion | -11.82pp |
| 1996-12-31 | 27.85% | $1.43 Billion | $5.14 Billion | +11.99pp |
| 1995-12-31 | 15.86% | $594.00 Million | $3.74 Billion | -- |
About Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines,… Read more